Видео с ютуба Protalix News

Protalix BioTherapeutics Q2 2025 Earnings Call

Protalix Biotherapeutics (PLX) in an Enviable Position

INVESTOR NEWS || THIS STOCK HAS A PARABOLIC MOVE COMING || MUST WATCH

Protalix Fireside Chat. CEO Dror Bashan, CFO Eyal Rubin and Zacks Analyst John Vandermosten

Protalix BioTherapeutics CEO on Biotechnology Breakthroughs

Protalix to Develop More Plant-Cell Drugs, CEO Says

News Update: Protalix (PLX) Gets Prescription Drug User Fee Act Action Date for Taliglucerase